GFAP and Hyperglycemia: In addition, ranirestat, an inhibitor of the enzyme aldose reductase, which has an early role in the development of DR [36], exerts neuroprotective effects by reducing GFAP accumulation and preventing hyperglycemia-associated structural damage of the retina [31].